[M-BACOD in advanced case of non-Hodgkin's lymphoma].
A M-BACOD regimen using an increased dose of Adriyamycin has been administered to 18 patients with non-Hodgkin's lymphoma. Sixty-three percent of the patients who had been previously untreated obtained a complete remission and the 2-year survival rate of those who evidenced a complete response reached 71%. The stage of the lymphoma was found to be a prognostic factor for a complete remission, while LDH and tumor response had an influence upon survival.